Market Place
Sourcing Support
EU Approves Calquence-Based Regimens for CLL Patients
07 Jun 2025 //
PRESS RELEASE
Enhertu+Pertuzumab Cuts Risk 44% in HER2+ Breast Ca Ph3
02 Jun 2025 //
BUSINESSWIRE
Camizestrant Reduced Risk of Disease Progression or Death by 56%
02 Jun 2025 //
BUSINESSWIRE
Camizestrant Cuts Risk 56% In ESR1+ HR+ Breast Cancer Trial
01 Jun 2025 //
BUSINESSWIRE
Imfinzi Regimen Cuts Progression Risk 29% In Gastric Cancer
01 Jun 2025 //
BUSINESSWIRE
Datroway Shows Promising Tumor Responses in Lung Cancer
01 Jun 2025 //
BUSINESSWIRE
Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel
31 May 2025 //
BUSINESSWIRE
Pfizer-Arvinas Breast Cancer Drug tops AstraZeneca
30 May 2025 //
REUTERS
AstraZeneca India approved for new use of Osimertinib
29 May 2025 //
EXPRESSPHARMA
Enforcement Report - Week of May 28, 2025
28 May 2025 //
FDA
Zentiva Inks 220M Deal for Former Astra Zeneca GI Drug in Europe
22 May 2025 //
FIERCE PHARMA
AZ, Merck Duke It out To Lead Oncologists’ Pharma Perceptions
22 May 2025 //
FIERCE PHARMA
Aptar Digital Health, AstraZeneca Partner on AI Screening
22 May 2025 //
BUSINESSWIRE
AstraZeneca`s record year at ASCO Advances Cancer Care
21 May 2025 //
BUSINESSWIRE
IDEA ranks Lilly, AZ as biopharma`s top Innovators, Inventors
20 May 2025 //
FIERCE PHARMA
TGA Seeks Feedback on International Clinical Trial Guidelines
19 May 2025 //
RAPS
Ph 3 trial shows Airsupra as standard rescue treatment in Asthma
19 May 2025 //
BUSINESSWIRE
Global Coalition Starts AZD1390 in GBM AGILE Trial
13 May 2025 //
PR NEWSWIRE
AstraZeneca to present respiratory research at ATS 2025
13 May 2025 //
BUSINESSWIRE
AZ`s Imfinzi checks off a win in high-risk bladder cancer study
10 May 2025 //
FIERCE PHARMA
Imfinzi® Regimen Shows Significant Improvement in Bladder Cancer
09 May 2025 //
BUSINESSWIRE
AstraZeneca`s Trastuzumab deruxtecan therapy approved by CDSCO
08 May 2025 //
EXPRESSPHARMA
AZ, Daiichi`s Enhertu tops SOC in early-stage breast cancer
08 May 2025 //
FIERCE PHARMA
Enhertu + THP Boosts Complete Response in Breast Cancer Trial
07 May 2025 //
BUSINESSWIRE
AstraZeneca`s enhertu improved pCR in early-stage breast cancer
07 May 2025 //
INDPHARMAPOST
Enhertu Boosts Response in High-Risk HER2+ Breast Cancer
07 May 2025 //
BUSINESSWIRE
Life Sciences Leaders Unify at Veeva Commercial Summit
06 May 2025 //
PR NEWSWIRE
AZ`s $300M cell therapy manufacturing site opens in Maryland
06 May 2025 //
FIERCE PHARMA
Pathos AI gets AZ funding as biotech plans to raise up to $400M
03 May 2025 //
ENDPTS
AZ`s Breztri set up for label expansion with 2 asthma trial wins
03 May 2025 //
FIERCE PHARMA
AstraZeneca`s `smoker`s lung` therapy meets main goals in trials
02 May 2025 //
REUTERS
AstraZeneca unfolds 1st TV ad for breast cancer med Truqap
30 Apr 2025 //
FIERCE PHARMA
AstraZeneca says potential US tariffs manageable
30 Apr 2025 //
REUTERS
AstraZeneca`s Truqap falls short in another phase 3 trial
30 Apr 2025 //
FIERCE PHARMA
AstraZeneca`s Q1 2025 Financial Results
29 Apr 2025 //
BUSINESSWIRE
Onco-Innovations` Inka Health Sign New Work with AstraZeneca Canada
24 Apr 2025 //
ACCESSWIRE
AstraZeneca says EU must invest to protect its `health sovereignty`
24 Apr 2025 //
REUTERS
Tempus AI in line for $200M from AstraZeneca cancer model deal
23 Apr 2025 //
FIERCE BIOTECH
AstraZeneca rejoins leading US drug lobby group after 2 year absence
23 Apr 2025 //
REUTERS
AstraZeneca returns to industry association PhRMA
22 Apr 2025 //
FIERCE PHARMA
Enhertu drives strong efficacy in first-line breast cancer
22 Apr 2025 //
BUSINESSWIRE
AstraZeneca unit sued over alleged monopoly on drug Soliris
17 Apr 2025 //
REUTERS
AstraZeneca Pharma India surrenders Olaparib marketing authorizat
16 Apr 2025 //
INDPHARMAPOST
EU pharma firms demand to stay in EU amid expected US tariffs
15 Apr 2025 //
REUTERS
AstraZeneca highlights infectious disease protection at ESCMID 2025
10 Apr 2025 //
INDPHARMAPOST
Datroway® EU approval for metastatic HR+, HER2- breast cancer.
08 Apr 2025 //
BUSINESSWIRE
Enhertu Approved in EU as First HER2 Therapy for HR+ Breast Cancer
05 Apr 2025 //
BUSINESSWIRE
Inka Health Completes Analytics for AstraZeneca Canada
03 Apr 2025 //
ACCESSWIRE
AstraZeneca Pharma India, Pharmaids, Dr. Agarwal`s in Briefs
01 Apr 2025 //
INDPHARMAPOST
AZ`s oral PCSK9 inhibitor halves bad cholesterol in phase 2
01 Apr 2025 //
FIERCE BIOTECH
AZ, MSK adopt tech firm`s data capture tool for phase 3 trial
01 Apr 2025 //
FIERCE BIOTECH
ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer
01 Apr 2025 //
BUSINESSWIRE
AZ`s Imfinzi wins perioperative FDA nod in bladder cancer
01 Apr 2025 //
FIERCE PHARMA
AZD0780, oral inhibitor, reduces LDL-C in PURSUIT Phase IIb Trial
31 Mar 2025 //
BUSINESSWIRE
TAGRISSO® reaffirmed as key therapy for EGFR-mutated lung cancer
25 Mar 2025 //
BUSINESSWIRE
Syneron Bio Announces Strategic Collaboration with AstraZeneca
24 Mar 2025 //
PR NEWSWIRE
AstraZeneca investing $2.5 B in China
22 Mar 2025 //
REUTERS
AstraZeneca`s Kavigale Receives Approval in Canada
21 Mar 2025 //
HEALTH CANADA
AstraZeneca signs Alteogen deal worth up to $1.35B
19 Mar 2025 //
FIERCE PHARMA
AstraZeneca`s $800M rare disease bet hits primary Ph 3 goal
17 Mar 2025 //
FIERCE BIOTECH
